PPB - Services

Complaints, Feedback and Enquiry

Falsified COVISHIELD vaccine identified in the WHO regions of Africa and South-East Asia

[featured_image]
  • Version
  • Download 23
  • File Size 439.28 KB
  • File Count 1
  • Create Date March 21, 2022
  • Last Updated March 21, 2022

Falsified COVISHIELD vaccine identified in the WHO regions of Africa and South-East Asia

This WHO Medical Product Alert refers to falsified COVISHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)) identified in the WHO African Region, and the WHO South-East Asia Region. The falsified products were reported to WHO in July and August 2021. The genuine manufacturer of COVISHIELD (Serum Institute of India Pvt. Ltd.) has confirmed that the products listed in this alert are falsified. These falsified products have been reported at patient level in Uganda, India and Myanmar.

Genuine COVISHIELD vaccine is indicated for active immunization of individuals 18 years or older for the prevention of coronavirus disease caused by the SARS-CoV-2 virus. The use of genuine COVID-19 vaccines should be in accordance with official guidance from national regulatory authorities.

Falsified COVID-19 vaccines pose a serious risk to global public health and place an additional burden on vulnerable populations and health systems. It is important to detect and remove these falsified products from circulation to prevent harm to patients.

Attached Files

FileAction
2021_08_20_Rapid alert_COVISHIELD.pdfDownload

Author

ppb_admin

Leave a comment

Your email address will not be published.